Lykos Therapeutics Faces Setback as FDA Rejects Midomafetamine for PTSD Treatment
Lykos Therapeutics, a U.S.-based biotech firm, has expressed concern over the impact of the FDA’s...
Lykos Therapeutics, a U.S.-based biotech firm, has expressed concern over the impact of the FDA’s...
Chugai Pharmaceutical Co., Ltd. (TYO: 4519), a subsidiary of Roche, has submitted a product approval...
Staidson (Beijing) Pharmaceutical Co., Ltd. (SHE: 300204) has announced that it has received approval from...
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that it has received clinical trial...
Lepu Scientech Medical Technology (Shanghai) Co., Ltd. (HKG: 2291) has announced that it has received...
Sino Medical Sciences Technology Inc. (SHA: 688108), a prominent player in China’s medical device sector,...
Zhejiang-based Vimgreen Pharma has announced the launch of a Phase II clinical trial for its...
Gilead Sciences Inc. (NASDAQ: GILD) has received accelerated approval from the U.S. FDA for its...
Astellas Pharma (TYO: 4503), a leading Japanese pharmaceutical company, has secured market approval in the...
Ma Zheng, the head of communication and government affairs for GSK plc (NYSE: GSK) in...
Shanghai Sanyou Medical Co., Ltd. (SHA: 688085), based in China, is set to acquire the...
Shandong Buchang Pharmaceuticals Co., Ltd. (SHA: 603858), based in China, has announced plans to enter...
Biogen Inc. (NASDAQ: BIIB), based in the U.S., and Japan’s Eisai Co., Ltd. have announced...
CStone Pharmaceuticals (HKG: 2616), a China-based biopharmaceutical company, has received approval from the National Medical...
Sansure Biotech Inc. (SHA: 688289), a China-based leader in molecular diagnostics, has secured marketing approval...
Qilu Pharmaceutical, based in China, has received marketing approval for its generic version of Bristol-Myers...
Eli Lilly & Co. (NYSE: LLY) has inaugurated its new R&D center in Boston’s Seaport...
Ascentage Pharma (HKG: 6855), based in China, has received approval from the National Medical Products...
Enhertu (trastuzumab deruxtecan), an HER2-targeted antibody-drug conjugate co-developed by AstraZeneca (NASDAQ: AZN, LON: AZN) and...
The School of Optometry at Hong Kong Polytechnic University has announced a new cooperation agreement...